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Abstract
Introduction—Polyneuropathy signs (Neuropathy Impairment Score, NIS), neurophysiologic 
tests (m+7Ionis), disability, and health scores were assessed in baseline evaluations of 100 patients 
entered into an oligonucleotide familial amyloidotic polyneuropathy (FAP) trial.
Methods—We assessed: 1) Proficiency of grading neurologic signs and correlation with 
neurophysiologic tests, and 2) clinometric performance of mNIS+7Ionis and its subscores and 
correlation with disability and health scores.
Results—The modified Neuropathy Impairment Score + 7 neurophysiologic tests (mNIS+7Ionis) 
sensitively detected, characterized and broadly scaled diverse polyneuropathy impairments. 
Polyneuropathy signs (NIS and subscores) correlated with neurophysiology tests, disability, and 
health scores. Smart Somatotopic Quantitative Sensation Testing of Heat as Pain 5 provided a 
needed measure of small fiber involvement not adequately assessed by other tests.
Discussion—Specially trained neurologists accurately assessed neuropathy signs as compared to 
referenced neurophysiologic tests. The score, mNIS+7Ionis, broadly detected, characterized, and 
scaled polyneuropathy abnormality in FAP, which correlated with disability and health scores.
Keywords
oligonucleotide trials; familial amyloid polyneuropathy (FAP); polyneuropathy signs; 
neurophysiologic tests; peripheral neuropathy; disability; proficiency
INTRODUCTION
Transthyretin amyloidosis (ATTR) is a fatal dominantly inherited disease due to >100 point 
mutations of transthyretin (TTR), a transport protein of thyroxine and retinol – binding 
protein mainly synthesized by the liver.2-12 Typically, the disease manifests in early or later 
adult life as a symmetric length-dependent sensorimotor-autonomic polyneuropathy, also 
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called familial amyloidotic polyneuropathy (FAP).11,13-18 The polyneuropathy may be 
overshadowed by cardiomyopathy or other organ involvement.12,19
Recently, ATTR has received increasing attention, because it is fatal, may be more common 
than usually recognized10,15 and has become treatable.14,20 Although still not adequately 
evaluated, orthotopic liver transplantation, resulting in marked reduction of circulating 
mutant TTR, appears to slow disease progression.21-23 Stabilization of circulating tetrameric 
protein TTR using Vyndaqel® or Diflunisal slows FAP progression.14,20 Oligonucleotide 
therapies directed at TTR messenger RNA have been shown to markedly reduce both mutant 
and wild plasma TTR levels and are in phase 3 clinical trials.24,25
In a previous retrospective review of Mayo Clinic, Rochester, MN, USA patients with FAP, 
we assessed the clinometric properties of NIS+7 (a composite score of polyneuropathy signs 
and neurophysiologic tests) to quantitate the overall kind and severity of polyneuropathy 
impairment in FAP.17 The score broadly characterized and quantified muscle weakness, 
muscle stretch reflex decrease, sensation loss of feet and hands, and neurophysiologic test 
abnormalities. From analysis of the data, 3 modifications of NIS+7 were recommended to 
more broadly and adequately represent the diversity and severity of polyneuropathy 
impairments: 1) assess sensation loss of both large and small fiber modalities 
somatotopically using validated approaches and suitable reference values; 2) assess only 
amplitudes of attributes of nerve conduction and include attributes of an upper limb nerve, 
e.g., the ulnar nerve; and 3) assess sudomotor decrease at distributed body sites.
In a recently published multinational study, rapid progression of FAP was demonstrated 
using the Neuropathy Impairment Score (NIS), and its severity was correlated with 
functional scales of locomotion.18
The ongoing Phase 3 FAP clinical trials with TTR lowering agents (IONIS-TTRRx and 
patisiran)24,25 use modifications of NIS+7 scores that have incorporated the first 2 of the 3 
recommended modifications suggested above. The modified NIS+7 scores differ slightly, 
and herein the score utilized in the IONIS-TTRRx trial (NEURO-TTR) is referred to as 
mNIS+7Ionis.
This study assessed the clinometric performance of polyneuropathy signs (NIS) and 
neurophysiologic tests (m + 7Ionis) in evaluation at baseline of the first 100 FAP patients 
entered into the NEURO-TTR trial. The following questions were addressed: 1) do NIS and 
its subscores and modified+7 neurophysiologic tests adequately detect, characterize, and 
scale polyneuropathy abnormalities and their severity in FAP; 2) can international 
neurologists, given special training and agreeing to grade abnormality specifically, 
accurately grade abnormality of polyneuropathy signs as inferred from correlations with 
abnormality of neurophysiologic tests; 3) do clinical signs and neurophysiologic test scores 
correlate with disability and health scores; and 4) are correlations of mNIS+7Ionis as strong, 
or stronger, than are components of mNIS+7Ionis with disability and health scores in FAP?
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MATERIALS AND METHODS
Brief description of Ionis-TTRRX Phase 3 Trial of FAP
This report is restricted to an evaluation of the baseline polyneuropathy assessments in 
duplicate of neuropathy signs (NIS), unmodified (+ 7) and modified neurophysiologic tests 
(m+7Ionis), and functional health and disability scores [amyloid gait score here called 
polyneuropathy disability score (PND), Dyck/Rankin and Inflammatory Neuropathy Cause 
and Treatment (INCAT) from Neuropathy Symptoms and Change (NSC)] and health scores 
(Norfolk-DN QOL, NSC, and SF-36) of the first 100 FAP patients enrolled into the 
NEURO-TTR trial (Ionis Pharmaceuticals, Inc. NCT01737398). All study subjects were 
required to sign written consent forms reviewed by the Institutional Review Boards of 
participating medical centers. IONIS-TTRRx is a second-generation 2′-O-(2-methoxyethyl) 
modified antisense oligonucleotide drug targeted to TTR. The binding of IONIS-TTRRx to 
the TTR messenger RNA results in degradation of the RNA and thereby reduces the 
production of TTR protein. Patients had to meet the following entry criteria at screening: an 
NIS ≥ 10 - ≤ 130, demonstrated tissue deposition of amyloid, a TTR mutation by 
genotyping, and age 18 to 82 years. In addition, patients were excluded if they had a prior 
history of liver transplantation, diabetes mellitus, or the presence of other causes of 
polyneuropathy and were not allowed to receive transthyretin stabilizing drugs during the 
study.
Description of Polyneuropathy Endpoints
The NIS has been described extensively and used in previously published therapeutic trials 
in chronic inflammatory demyelinating polyradiculoneuropathy,26,27 polyneuropathy 
associated with monoclonal gammopathies of undetermined significance,28 and diabetic 
sensorimotor polyneuropathies 29,30. The NIS comprises scores of muscle weakness (NIS-
W, 0-192), decrease of muscle stretch reflexes (NIS-R, 0-20), and abnormality of 4 sensory 
modalities of sensation loss in the toes and fingers (NIS-S, 0-32) – the total NIS score may 
vary from 0 to 244. The NIS components (clinical assessments) are the same in NIS+7 as in 
modification of NIS+7 (mNIS+7Ionis).
The NIS+7 and mNIS+7Ionis differ in the neurophysiologic tests in the +7. The +7 tests in 
the NIS+7 include 5 attributes of nerve conduction [fibular nerve compound muscle action 
potential (CMAP) amplitude, motor nerve conduction velocity (MNCV) and motor nerve 
distal latency (MNDL), tibial nerve MNDL, and sural nerve sensory nerve action potential 
(SNAP) amplitude], vibratory detection threshold of the great toe using CASE IVc, (WR 
Medical Electronics, Maplewood, MN, USA), and heart rate decrease with deep breathing 
(HRdb) also assessed by equipment from WR Medical Electronics, Inc. Each of the +7 tests 
is expressed as a normal deviate (nd) from percentiles derived from reference values 
obtained in a study of healthy subjects from Olmsted County, MN, USA.31.
To provide a more accurate and representative assessment of the kind and distribution of 
sensation loss in the mNIS+7Ionis, the vibration detection threshold of the great toe was 
replaced by Smart Somatotopic Quantitative Sensation Testing (S ST QSTing) of touch-
pressure (TP) and heat as pain 5 (HP5) (of 1-10 severity) of the body surface area.14,17 As 
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directed by the algorithm, up to 10 distributed unilateral anatomical sites are tested. Healthy 
subject reference values are available for all 10 assessed sites and for both touch-pressure 
and heat as pain 5 sensation (reference data unpublished). The automated algorithm of 
testing of S ST QSTing assumes that sensation loss in FAP is symmetric and length 
dependent. For a patient with only distal sensation loss of lower and upper limbs, only 4 
distal sites of 1 side of the body require testing. For a patient with generalized sensation loss, 
a variable number of sites (up to 10) may need to be tested. The S ST QSTing score ranges 
from 0-80 depending on the severity and distribution of sensation loss. In addition, the mNIS
+7Ionis uses different attributes of nerve conduction than were used in NIS+7, including an 
upper limb nerve. The attributes in mNIS+7Ionis include CMAPs of ulnar, fibular, and tibial 
nerves and SNAPs of ulnar and sural nerves. This change was made to employ measures of 
amplitude over measures of conduction velocity or distal latency. Attributes of nerve 
conduction are expressed as normal deviates from percentiles as described for mNIS+7Ionis. 
The heart rate decrease with deep breathing (HRdb) remains unchanged in mNIS+7Ionis from 
that used in NIS+7.32,33
Approaches Used to Accurately Assess Clinical Signs and Neurophysiologic Tests
Because mNIS+7Ionis uses assessment of clinical neuropathy signs and neurophysiologic 
tests, emphasis was placed on choice of investigators, training, proficiency, and adequate 
handling of their clinical measurements. Neurologists chosen for the trial had to be faculty 
neurologists who planned to evaluate the same patient over the duration of the trial.34 They 
were trained neurologists or clinical neurophysiologists, typically on the teaching staff of a 
Neurology department in a medical school. To obtain uniformity of grading, all received 
special training and certification by members of the Mayo Clinic Peripheral Neuropathy 
Research Laboratory (MC PNRL). Healthy subjects and patients with FAP were used in 
training. In assessment of neuropathy signs, specificity was emphasized over sensitivity 
based on results of recently published Cl vs NPhys trials results.34-36 As much as was 
possible at each clinical trial site, separate personnel performed the different neuropathy 
assessments, i.e., neurologic examinations, nerve conduction studies, smart somatotopic 
quantitative sensation testing, and autonomic testing. Study site personnel did not summate 
test scores; this was done later at the MC PNRL. Several additional strategies were used to 
make independent assessments. The duplicate neuropathic assessments had to be separated 
by at least 24 hours. The tracings of attributes of nerve conduction were carefully reviewed 
in the MC PNRL by one of the authors (WJL) to evaluate the adequacy of test performance. 
The conversion of nerve conduction measurements to percentiles and normal deviates was 
done later by programmed calculations in the MC PNRL. The performance of S ST QSTing 
and HRdb was directed by smart algorithms and reference values.
After special training and certification, and prior to onset of the trial, examiners submitted 
test results of all neuropathy evaluations of a healthy subject aged < 50 years and another ≥ 
50 years. This was done to ensure adequate performance of the tests and approval of test 
performance by the MC PNRL personnel. In assessment of polyneuropathy signs, 
neurologists were asked to grade as abnormal only unequivocal abnormality related to FAP 
and taking age, gender, and anthropomorphic variables into account.34,35 Standard paper/
electronic forms were used for entry of neuropathic signs, symptoms, and neurophysiologic 
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tests.1,36 Examiners were asked to use a scribe to record neuropathy signs as they were 
elicited to avoid transcription error.27 Signs and neurophysiologic test results were 
transmitted electronically to the MC PNRL.
Neurophysiologic tests were done by trained and certified clinical neurophysiologists or 
their technologists, both of whom had received specially prepared syllabi and special 
training. For assessment of S ST QSTing, automated and highly standardized equipment 
(prototypes developed at Mayo Clinic, Rochester, MN and fabricated to industry standards at 
WR Medical Electronics, Maplewood, MN, USA) was made available to every clinical site. 
The S ST QSTing algorithms of testing and estimated thresholds were developed by one of 
the authors (PJD) and programmed for use for QSTing by WR Medical Electronics. It uses 
highly standardized and automated stimuli, algorithms of testing, and finding threshold and 
reference values, and its accuracy and proficiency has been demonstrated.33
Neuropathic Symptoms, Disability, and Health Scores
Three health and disability scores were used to evaluate overall functional disability: the 
PND, Dyck/Rankin score, and the INCAT from the NSC score. The INCAT from NSC score 
assesses disability due to weakness of distal and proximal muscles of upper and lower limbs 
and scores abnormality from 1 to 10. Also assessed were 2 health scores, Norfolk QOL-DN 
and the SF-36.
Analysis Plan
At a conceptual level, abnormality of clinical signs, symptoms, and neurophysiologic tests 
were set at a fifth or first percentile level and as corrected for age, gender, and 
anthropomorphic variables. In this study, such reference values were available from a 
healthy subject cohort drawn from the Olmsted County, MN, USA population with subjects 
excluded based on neurologic evaluation and review of their medical records.31,37 
Individuals with diabetes, metabolic diseases, or polyneuropathy were excluded. Highly 
standardized approaches were used to evaluate attributes of nerve conduction, quantitative 
sensation, and autonomic tests.31,37 These neuropathic test results were assessed for the 
influence of age, gender, and anthropomorphic variables. Results were expressed as 
measured values, percentiles, and normal deviates.
Data were analyzed using standard statistical techniques with a primary intention to 
quantitate neuropathy signs and neurophysiologic test abnormalities and to describe 
associations between the various FAP measurements including NIS (pts), Σ5 NCs (nds), S 
ST QSTing (pts), S ST QSTing of TP (pts), S ST QSTing of HP5 (pts), HRdb (nds), and 
dysfunction, disability, and health scores. Test/re-test reproducibility results were assessed 
for a significant degree of agreement using the Krippendorff alpha.
The accuracy of individual clinical signs was assessed by Spearman correlations with a 
comparable neurophysiologic test, with the 2 evaluations determine independently. Eleven 
such comparisons were possible. In the 11 available comparisons, the neurophysiologic tests 
were judged to be the gold standard evaluation, because they were more objective, standard, 
quantitated, and referenced as compared with the neuropathic signs clinically evaluated. For 
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a broader exploration of the correlations among assessed neuropathy signs (NIS) or their 
subscores (NIS-W, -R, or –S), they were compared to composite disability or health scores.
In several tables, Spearman rank correlation coefficients (r) and P-values (P) were combined 
into 6 strata to provide simplified expressions of strength and significance of correlations.
Multiple comparisons were conducted, so a Bonferroni correction was applied to the P-
values as needed in Table 1. When adjusted P-values are reported, they are clearly noted. 
Statistical analysis was conducted using the SAS System version 9.3 (Cary, NC).
RESULTS
Demographic and baseline characteristics
The patients were recruited from 16 medical centers from 6 countries: USA (65), Portugal 
(14), France (13), England (5), Italy (2), and Brazil (1). Seventy-six were women, and 24 
were men. Their median age was 65, range 27 – 81 years. Non-USA patients (n=35) had a 
higher frequency of Val30met mutations (66%) than did USA patients (25%).
The test/re-test reproducibility of signs (NIS), symptoms (NSC), attributes of nerve 
conduction (i.e., Σ5NC, S ST QSTs of TP or HP5), and HRdb are given in Table 1. Note the 
high reproducibility values for neuropathic signs (NIS), nerve conductions (Σ5NCs) and 
HRdb. The reproducibility value for S ST QSTing is somewhat lower, especially for touch-
pressure sensation. Because all of the duplicate evaluations were performed within a day or 
within a few days of each other and by the same examiners, the adequacy of test/re-test 
reproducibility can be questioned. By contrast, the m+7Ionis neurophysiologic test 
reproducibility results should not have been influenced (or to a lesser degree) by patient or 
examiner recall of preceding evaluations or test results, because these tests are less 
subjective.
Characterization of FAP Impairments Using mNIS+7Ionis and Detection, Scaling and Ceiling 
Effects
The composite score mNIS+7Ionis and its subscores broadly characterized and quantitated 
distributed muscle weakness, muscle stretch reflex decrease, and large and small fiber 
sensation loss. As seen in Figure 1, autonomic impairments were probably not adequately 
assessed by HRdb, because this test could not be performed in about one-third of patients 
due to cardiac arrhythmia or electronic pacing. Many subscores had some values at 0 in 
keeping with inclusion of mild FAP patients or those with limited types of dysfunction. In 
the S ST QSTing test, a score of 0 was observed for HP5 in 22 patients, and 5 patients did 
not have an abnormality of nerve conduction. Score values at ceiling might constitute a 
greater problem than do scores at zero, since such values prevent recognition of worsening 
in subsequent evaluations. Values of scores at ceiling included NIS—reflexes (n = 8), S ST 
QSTing of HP5 (n= 1), and HRdb (n=7).
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Correlation of Individual Polyneuropathy Signs with a Closely Matched Neurophysiologic 
Test Assessing Accuracy of Assessment of Clinical Polyneuropathy Signs
Considering the 37 individual neuropathy signs assessed in NIS, there were 11 for which a 
closely matched individual neurophysiologic test was available for comparison. For these 11 
pairs of evaluations, the neurophysiologic test served as the gold standard assessment, 
because it was a highly standardized, quantitated, and referenced assessment. As shown in 
Table 2, 9 of the 11 clinical signs correlated strongly with their closely matched 
neurophysiologic test, i.e., high values of correlation coefficients and significance. To 
illustrate, weakness of toe or ankle dorsiflexion correlated closely with fibular nerve 
compound muscle action potential (CMAP) amplitudes. Seven additional signs correlated 
closely with comparable neurophysiologic tests. However, significant correlations were not 
found between clinical testing of touch-pressure or pin prick sensation and quantitative 
sensation tests of hands.
Correlation of Composite Measure of Polyneuropathy Signs (NIS) with Neurophysiological 
Tests (m+7Ionis)
As shown in Table 3, strong correlations were observed between assessments of clinically 
assessed neuropathic signs (NIS) or symptoms (NSC) and neurophysiologic tests. The 
correlation of polyneuropathy signs (NIS) with m+7Ionis neurophysiologic tests performed 
as well or better than did any subscores of signs with neurophysiologic tests. Polyneuropathy 
signs (NIS) and symptoms (NSC) correlated more strongly with the modified attributes of 
nerve conduction using only motor and sensory amplitudes (the attributes used in mNIS
+7Ionis) than with those used in NIS+7 attributes (used for study of diabetic polyneuropathy) 
(data not shown). Clinical measures of polyneuropathy signs or symptoms correlated 
strongly with somatotopic assessment of touch-pressure but not with somatotopic 
assessment of HP5; the latter is a measure of small sensory fiber dysfunction. Similarly, 
scored signs (NIS) and symptoms (NSC) did not correlate with HRdb. By contrast, the 
autonomic sub-score of NSC correlated at a low level of significance with measured HP5 (S 
ST QSTing of HP5) and with HRdb.
Correlation of Neuropathy Signs and Neurophysiologic Tests with Disability and Health 
Scores
The data are shown in Table 4. Considering the correlation between signs and 
neurophysiologic tests, the strongest correlations occurred between mNIS+7Ionis and 
disability and health scores. Almost as strong correlations were obtained for NIS total or 
from the weakness (NIS-W) subscore and disability and health scores. The correlation 
between reflexes (NIS-R) and disability and health scores was not as strong. The 
correlations between symptom scores (NSC) provided confirmatory information. Symptoms 
of weakness (NSC weakness) and sensory loss (NSC sensation) correlated strongly with 
disability and health scores. Scores of positive neuropathic sensory symptoms, pain, and 
autonomic scores correlated at lower levels of significance with disability and health scores. 
Somatotopic evaluation of touch-pressure but not of heat as pain sensation correlated with 
all disability and health scores.
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In Figure 2, we show the distribution of mNIS+7Ionis score values of FAP patients staged by 
the PND. Scored values are significantly different among the three stages.
DISCUSSION
Previously published cohort studies of FAP2,6,7,11,15,16,18 found considerable variability in 
age of onset, clinical manifestations, and course of this polyneuropathy. To illustrate, the 
somatotopic distribution and severity of muscle weakness, muscle stretch reflex decrease, 
the balance of large to small fiber sensation loss, and autonomic deficits varied considerably 
among patients. This variability of clinical expression, the rarity of FAP, and the desire to 
include a representative cohort of FAP impairments were important considerations in the 
choice to use a composite neuropathy score as an outcome measure in the NEURO-TTR 
trial. mNIS+7Ionis was designed to somatotopically quantitate muscle weakness and large 
and small fiber sensory loss. Autonomic dysfunction, however, was not assessed 
somatotopically and, as shown here, HRdb is not an adequate outcome measure of small 
fiber involvement in FAP.
Neurophysiologic test results (m+7) were added to a score of clinical signs (NIS) for 2 
reasons: 1) for m+7Ionis tests to serve as reference standards against which accuracy of 
assessment of clinical signs could be compared, and 2) to aid in comprehensive scoring of 
FAP impairments. We reasoned that use of such composite scoring would not prevent it from 
demonstrating a meaningful beneficial effect, assuming that an efficacious treatment would 
benefit all kinds and severities of FAP impairments.
In our analysis of the first 100 FAP patients from 6 different countries entered into the 
NEURO-TTR trial, we found that a broad range of polyneuropathy functional impairments 
and severities had been recruited. Typically, the composite score mNIS+7Ionis and its 
component scores detected and broadly scaled these abnormalities with sufficient room to 
recognize expected worsening. From a review of the distribution of the kind and severities of 
polyneuropathy signs and neurophysiologic test abnormalities, it appeared that the goal of 
recruiting a broad range of severities of FAP severities is being achieved in this trial. 
Component scores of mNIS+7Ionis without abnormality at baseline evaluations (mean of 2 
evaluations) were: NIS-R (n=7), S ST QSTing of HP5 (n=22), and several other endpoints 
(Figure 1). None of the recruited patients had mNIS+7Ionis scores at ceiling. However, 
ceiling scores were observed for some subscores: NIS reflexes (n=8), S ST QSTing of HP5 
(n=1), and HRdb (n=7). Overall, we judged that mNIS+7Ionis broadly detected and scaled 
polyneuropathy abnormality over a broad range of different expressions and severities.
Availability of highly standardized neurophysiologic tests, reference values of nerve 
conduction, and quantitative sensation tests in the mNIS+7Ionis composite score allowed us 
to test for the accuracy of closely matched clinical signs. Most clinical signs had been 
accurately assessed by international neurologists. This conclusion was supported by the 
significant correlation of composite scores of clinical signs with neurophysiologic tests. It is 
direct evidence that neurologists, given special training and certification, had accurately 
assessed polyneuropathy signs.
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From our correlation studies of polyneuropathy signs as compared to neurophysiologic tests, 
we also observed that correlations were much stronger for some composite scores of nerve 
conduction than for others. Thus, those chosen for m+7Ionis performed much better than 
those in +7 (the latter chosen for study of diabetic polyneuropathy and emphasizing 
attributes of nerve conduction velocity and distal latencies). We also note that the strong 
correlations between assessed neuropathy signs and neurophysiologic tests came from 
assessments made at 16 medical centers located in 6 different countries, providing evidence 
that mNIS+7Ionis can be assessed accurately and proficiently at multiple medical centers and 
in different countries. However, we judge that the good clinometric performance of 
neurologists and neurophysiologists observed here came from performance related to 
insights gained from previously conducted Clinical vs Neurophysiologic Trials (Cl vs 
NPhys)33-35,38,39. The choice of expert neurologists and clinical neurophysiologists, special 
training sessions to grade abnormality specifically using appropriate reference values, and 
quality control at a central reading and quality assurance center probably contributed to the 
observed accuracy of polyneuropathy measurements.
How broadly applicable is mNIS+7Ionis for therapeutic trials in other countries or other 
neuropathies? From our results it appears that rigorous trials are possible in multiple 
countries assuming that the approaches found to be useful in this trial are utilized. However, 
whether mNIS+7Ionis would find usefulness in trials of other polyneuropathies cannot be 
inferred from the results of this trial.
Another question, not directly addressed in this trial, is whether mNIS+7Ionis can be scored 
or utilized without the involvement of MC PNRL personnel. We assume that it can, knowing 
that normative reference values of attributes of nerve conduction are widely available and 
that reference values of quantitative sensation and autonomic tests will increasingly be 
published or made available to users by neurophysiologic instrument makers.
This study has demonstrated that accurate grading of clinical neuromuscular impairments 
can be performed to the degree that it correlates with neurophysiologic tests and other health 
outcomes in FAP. The clinical approaches to accurate grading of polyneuropathy signs was 
inferred from results of Cl vs NPhys Trials 1 and 2.34,35 In Cl vs NPhys trial 1,34 12 
international neuromuscular experts evaluated and recorded the polyneuropathy signs of 24 
patients with diabetes and with and without polyneuropathy. The appearances and voices of 
patients were masked. Each patient was examined on a second occasion. In this trial , the 
experts markedly over-reported polyneuropathy signs and the diagnosis of polyneuropathy 
as compared to independently assessed, referenced, and sensitive nerve conduction 
abnormality. In addition, their judgment of abnormality of polyneuropathy signs and 
diagnosis of polyneuropathy were excessively variable among themselves. When the same 
trial was repeated approximately 1 year later,35 but on this occasion employing a consensus 
process emphasizing more specific use of “unequivocal abnormality” of signs for the 
diagnosis of polyneuropathy, an improvement in accuracy and proficiency resulted. 
Therefore, for the conduct of the NEURO-TTR trial of FAP and as discussed in Materials 
and Methods, a series of steps were taken to encourage neurologists to grade abnormality of 
polyneuropathy signs using specific criteria, comparison to healthy subjects, and to be 
objective and specific in their assessments. In their judgment of neuropathic abnormality, 
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neurologists were asked not to include signs attributable to old age, previous or concurrent 
disease, or injury other than FAP. In addition, all of the evaluations underwent surveillance 
at the central MC PNRL to encourage compliance with these standards.
The availability of m+7Ionis neurophysiologic test results in the mNIS+7Ionis score provided 
a built-in standard by which the accuracy of clinical signs could be judged. It was reassuring 
that most clinical signs for which a comparable neurophysiologic test had also been 
measured were found to be strongly correlated. Furthermore, it was reassuring that severity 
of polyneuropathy signs or symptoms assessed more broadly also correlated with 
neurophysiologic tests.
It is an important finding of this study that the entire score NIS (and even mNIS+7Ionis) 
performed as well or better than any of its subscores. This fact provides evidence that we 
have not included subscores that dilute the correlation of the overall scores. We also assessed 
whether the different symptom or disability scores performed as well or better than NIS or 
of one of its subscores in correlation with neurophysiologic tests. They did not, with 2 
exceptions, i.e., S ST QSTing of HP5 and HRdb. Whereas NIS and its subscores did not 
correlate with somatotopic assessment of HP5 or with HRdb, the autonomic subscores of 
NSC did.
The question of whether small fiber sensory (S ST QSTing of HP) or autonomic (HRdb) 
dysfunction measures should be included in mNIS+7Ionis needs to be considered, be because 
S ST QSTing of HP5 did not correlate with most other polyneuropathy measures in mNIS
+7Ionis. Also, test/retest reproducibility was not as high as it was for some other neuropathy 
measurements. Nevertheless, we judge that S ST QSTing of HP5 should be included in 
mNIS+7Ionis, because selective small fiber sensory loss would not be adequately assessed 
and this abnormality occurs to a marked degree in a subset of FAP patients.
The strong correlations of mNIS+7Ionis or its subscores with disability and health scores was 
helpful in demonstrating that the entire score provided as strong or stronger correlations with 
disability or health scores than did their component subscores. However, we observed that 
some of the component subscores, e.g., NIS, NIS-W, NSC-W and others, performed very 
well also.
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FAP Familial amyloidotic polyneuropathy
Health Scores Norfolk-DN-QOL, NSC and SF-36
HP5 Heat as pain 5 (of 1-10 severity) as tested by CASE IVc, 
WR Medical Electronics; Maplewood, MN
HRdb Heart rate decrease with deep breathing
INCAT Inflammatory neuropathy cause and treatment
MC PNRL Mayo Clinic Peripheral Nerve Research Lab
MNCV Motor nerve conduction velocity
MNDL Motor nerve distal latency
NC Nerve conduction
ND Normal deviate
NIS Neuropathy Impairment Score
NIS-W NIS of weakness
NIS-R NIS of muscle stretch reflexes
NIS-S NIS of clinical sensation of toes and fingers
NSC Neuropathy Symptoms and Change Score
mNIS+7Ionis Modified NIS + 7 score (neurophysiologic tests used in 
Ionis-TTRRX clinical trial in FAP)
PND Polyneuropathy disability score, also called amyloid gait 
stage
S ST QSTing SMART Somatotopic Quantitative Sensation Testing using 
CASE IVc, WR Medical Electronics, Maplewood, MN, 
USA
SNAP Sensory nerve action potential
TP Touch pressure sensation
TTR transthyretin
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Figure 1. 
The distribution of the measured values (mean of the 2 assessments) of the components of 
mNIS+7Ionis of the first 100 patients entered into IONIS-TTRRX Phase 3 FAP trial. Note 
that the clinical measures of weakness, muscle stretch reflexes, and clinical sensation scale 
abnormality with only a small ceiling effect observed for NIS reflexes. Among the clinical 
neurophysiological tests, scaling is robust for most tests, but approximately one-fourth of 
patients have no abnormality of Somatotopically assessed heat as pain 5 (HP5). Heart rate 
decrease with deep breathing was at ceiling in 7 patients. The data in this figure illustrate 
that mNIS+7Ionis represents the kind and range of severities of functional polyneuropathy 
abnormalities that occur in FAP. While muscle weakness, muscle stretch reflexes, and 
sensation loss of both large and small sensory fibers are broadly represented in the score, 
autonomic dysfunction is inadequately represented, because of frequent cardiac arrhythmias 
and electronic pacing.
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Figure 2. 
The mNIS+7Ionis score values of patients who have stage 1, 2, and 3 PND abnormalities.
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Table 1
The Test/Re-test Reproducibility of Baseline Values of Neuropathy Signs, Nerve Conduction Tests, Smart 
Somatotopic Quantitative Sensation Tests, and Heart Rate Decrease with Deep Breathing
Test
Baseline 1 Baseline 2
α † 95% CI
n* Median Range n* Median Range
NIS Total (points) 94 43.5 4.0 - 102.8 93 42.0 3.0 - 92.5 0.97 (0.96, 0.98)
mod. Σ 5 NC (nds) 94 11.9 1.2 - 17.7 94 11.6 −0.7 - 17.7 0.98 (0.97, 0.99)
S ST QST (points) 91 20.0 0.0 - 76.0 89 20.0 0.0 - 58.0 0.57 (0.36, 0.75)
S ST QST TP (points) 91 10.0 0.0 - 40.0 89 10.0 0.0 - 38.0 0.44 (0.22, 0.65)
S ST QST HP:5 (points) 91 4.0 0.0 - 40.0 89 4.0 0.0 - 40.0 0.65 (0.51, 0.78)
HRdb (nds) 57 −1.7 −3.7 - 1.9 56 −1.6 −3.7 - 0.7 0.93 (0.88, 0.96)
INCAT from NSC
(points) 96 3.0 0.0 - 10.0 97 3.0 0.0 - 10.0 0.94 (0.91, 0.96)
*
Missing values account for the numbers being <100. For NIS (points) and NSC (INCAT) a single or double evaluation has been performed on all 
100 patients. For the other listed endpoint, a somewhat lesser number is used.
†
Krippendorff alpha
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Table 2
Correlation Coefficients and Statistical Significance of Individual Neuropathy Signs and Neurophysiologic 
Tests Using Spearman Rank Correlations in ISIS Baseline Study of 100 FAP Patients (n = 94 or 95)
Test
Mean
Fibular
CMAP§
nd
Mean
Tibial
CMAP
nd
Mean
Ulnar
CMAP
nd
Mean
S ST
QSTing¶
TP Hand
pts
Mean
S ST
QSTing
TP Foot
pts
Mean
S ST
QSTing
HP:5
Hand
pts
Mean
S ST
QSTing
HP:5
Foot
Pts
Mean Values of Neuropathic Signs 
(NIS 23, 21, 22, 24, 15, 30, 34, 31 
and 35) or Symptoms
(NSC 20 and 21)
NIS # 23 r* −0.62
p† <0.0001
NIS # 21 r* −0.56
p† <0.0001
NIS # 22 r* −0.41
p† <0.0001
NIS # 24 r* −0.35
p† 0.0005
NIS # 15 r* −0.47
p† <0.0001
NIS # 30 r* 0.16
p† 0.1268
NIS # 34 r* 0.47
p†
NIS # 23 = toe extensors
  #21 = ankle dorsiflexors
  #22 = ankle plantar flexors
  #24 = toe flexors
  #15 = finger spread
  #30 = touch pressure (finger)
  #34 = touch pressure (toe)
  #31 = pin-prick (finger)
  #35 = pink-prick (toe)
NSC # 20 = loss of touch
  # 22 = loss of pain sensation
<0.0001
NIS # 31 r* 0.19
p† 0.0666
NIS # 35 r* 0.39
p† <0.0001
NSC 
Severity 
#
20
r* 0.38
p† 0.0002
NSC 
Severity 
#
22
r* 0.57
p† <0.0001
*Spearman rank correlations
†Shaded P-values indicate the test was significant at the 0.05 level. If a Bonferroni correction for multiple tests is used, the cutoff is 0.0045.
§CMAP = compound muscle action potential amplitudes
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¶S ST QSTing = smart quantitative sensation testing
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Table 3
Correlation Coefficients and Statistical Significance of Composite Scores of Polyneuropathy Signs (NIS) or 
Symptoms (NSC), and Neurophysiologic Tests (n = 100)
Test
r.pa
Mean
Modified
+ 7 tests
(nds and
pts)
Mean
modifie
d
Σ 5
NCc
(nds)
Mean
VDT
(nd)d
Mean
S-ST
QSTinge
TPf
(pts)
Mean
S-ST
QSTing
HP:5g
(pts)
Mean
HRdbh
(pts)
Mean NIS Total (pts) 1 1 2 1 NS NS
Mean NIS Weakness (pts) 1 1 3 1 NS NS
Mean NIS Reflexes (pts) 5 4 NS 3 NS NS
Mean NIS Sensation (pts) 1 1 1 2 3 NS
Mean INCAT from NSC (pts) 2 2 NS 2 NS NS
Mean NSC Weakness severity
(pts) 2 3 NS 1 NS NS
Mean NSC Sensation severity
(pts) 2 3 2 2 NS NS
Mean NSC PNSSi severity
(pts) NS NS 5 3 NS NS
Mean NSC Pain severity (pts) NS NS NS NS NS NS
Mean NSC Autonomic severity
(pts) 2 2 NS 3 5 3
a
r.P statistical category from Spearman rank correlations and P-values:
r category: 1 = r ≥ 0.5 or r ≤ −0.5; 2 = r ≥ 0.25 to r < 0.5 or r ≤ −0.25 to r > −0.5; 3 = r > −0.25 to r < 0.25.
P-value category: 1 = P ≤ 0.0001; 2 = P > 0.0001 to p ≤ 0.005; 3 = P > 0.005 to p ≤ 0.05; NS = P > 0.05.
r.P category: 1 if 1,1 (r category, P-value category); 2 if 1,2 or 2,1; 3 if 2,2; 4 if 2,3 or 3,2; 5 if 3,3.
bΣ 5 NCs (nds) = the sum of the normal deviates from percentiles of fibular nerve compound muscle action potential (CMAP) amplitudes, motor 
nerve conduction velocities (MNCV) and motor nerve distal latency (MNDL), tibial MNDL, and sural nerve action potential (SNAP) amplitudes.
c
modified Σ 5 NCs (nds) = the sum of the normal deviates from percentiles of ulnar, fibular, and tibial nerve CMAPs and ulnar and sural SNAPs.
dVDT = Vibratory Detection Threshold
eS ST QSTing = Smart Somatotopic Quantitative Sensation Testing
f
TP = Touch Pressure
g
HP:5 = Heat as Pain 5 QSTing Threshold
h
HRdb = Heart Rate Response to Deep Breathing
i
PNSS = Positive Neuropathic Sensory Symptoms
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Table 4
Correlation Coefficients and Statistical Significance of Composite Scores of Polyneuropathy Signs (NIS), 
Symptoms (NSC), or Neurophysiologic Tests and Health Scores (n=100)
Test
r.P*
Norfolk
Score
Amyloid
Gait
Stage
(PND)
Dyck/
Rankin
Score
Mean
INCAT
from
NSC
(pts)
SF-36 Health
Score
Physical
Health
Summary
Measure
Mean Modified NIS + 7 tests (nds and pts) 1 1 1 1 2
Mean NIS Total (pts) 2 1 1 1 2
Mean NIS Weakness (pts) 2 1 1 1 2
Mean NIS Reflexes (pts) 3 3 3 3 5
Mean NIS Sensation (pts) 3 1 2 2 4
Mean NSC Weakness severity (pts) 1 1 1 1 1
Mean NSC Sensation severity (pts) 1 3 3 2 2
Mean NSC PNSS† severity (pts) 1 NS 5 3 2
Mean NSC Pain severity (pts) 1 NS NS 5 3
Mean NSC Autonomic severity (pts) 3 NS 2 2 2
Mean Σ 5 NC§ NS 3 3 NS NS
Mean S-ST QSTing¶; TP** (pts) 1 2 3 2 2
Mean S-ST QSTing HP:5†† (pts) NS NS NS NS NS
*
r.P statistical category from Spearman rank correlations and P-values: r category: 1 = r ≥ 0.5 or r ≤ −0.5; 2 = r ≥ 0.25 to r < 0.5 or r ≤ −0.25 to r > 
−0.5; 3 = r > −0.25 to r < 0.25 P-value category: 1 = P ≤ 0.0001; 2 = P > 0.0001 to P ≤ 0.005; 3 = P > 0.005 to P ≤ 0.05; NS = P > 0.05 r.p category: 
1 if 1,1 (r category, p-value category); 2 if 1,2 or 2,1; 3 if 2,2; 4 if 2,3 or 3,2; 5 if 3,3
†
PNSS = Positive Neuropathic Sensory Symptoms
§Σ 5 NCs (nds) = the sum of the normal deviates from percentiles of fibular nerve compound muscle action potential (CMAP)
¶S ST QSTing = Smart Somatotopic Quantitative Sensation Testing
**
TP = Touch Pressure
††
HP:5 = Heat as Pain 5 QSTing Threshold
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